Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Sands Capital Alternatives, LLC | 13.02M | $26.0M | 9.86% | -- | 2026-06-30 |
| Soleus Capital Management, L.P. | 10.88M | $22.0M | 8.24% | -- | 2026-06-30 |
| Trails Edge Capital Partners, LP | 9.05M | $18.0M | 6.86% | +994.0K | 2026-06-30 |
| Fairmount Funds Management LLC | 8.63M | $17.0M | 6.53% | -- | 2026-06-30 |
| BlackRock, Inc. | 7.77M | $15.0M | 5.88% | +1.46M | 2026-06-30 |
| ADAR1 Capital Management, LLC | 7.39M | $14.0M | 5.59% | +780.6K | 2026-06-30 |
| Blackstone Inc. | 5.94M | $12.0M | 4.50% | -- | 2026-06-30 |
| Siren, L.L.C. | 5.85M | $11.0M | 4.43% | -- | 2026-06-30 |
| Commodore Capital LP | 5.40M | $10.0M | 4.09% | -- | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.94M | $10.0M | 3.74% | +484.7K | 2026-06-30 |
